• 5365 Citations
  • 35 h-Index
1993 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Alessandro Morabito is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
docetaxel Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2019

  • 5365 Citations
  • 35 h-Index
  • 179 Article
  • 6 Review article
  • 1 Conference contribution
  • 1 Comment/debate

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation

Camerlingo, R., Miceli, R., Marra, L., Rea, G., D’Agnano, I., Nardella, M., Montella, R., Morabito, A., Normanno, N., Tirino, V. & Rocco, G., Jan 1 2019, In : PLoS One. 14, 7, e0219597.

Research output: Contribution to journalArticle

Open Access
Epithelial-Mesenchymal Transition
lung neoplasms
Conditioned Culture Medium
MicroRNAs
Lung Neoplasms

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation

Camerlingo, R., Miceli, R., Marra, L., Rea, G., D'Agnano, I., Nardella, M., Montella, R., Morabito, A., Normanno, N., Tirino, V. & Rocco, G., 2019, In : PLoS One. 14, 7, p. e0219597

Research output: Contribution to journalArticle

Epithelial-Mesenchymal Transition
lung neoplasms
Conditioned Culture Medium
MicroRNAs
Lung Neoplasms
Biological Factors
Antineoplastic Agents
clinical trials
Clinical Trials
Costs and Cost Analysis

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial

Landi, L., Chiari, R., Tiseo, M., D'Incà, F., Dazzi, C., Chella, A., Delmonte, A., Bonanno, L., Giannarelli, D., Cortinovis, D. L., De Marinis, F., Borra, G., Morabito, A., Gridelli, C., Galetta, D., Barbieri, F., Grossi, F., Capelletto, E., Minuti, G., Mazzoni, F. & 8 others, Verusio, C., Bria, E., Alì, G., Bruno, R., Proietti, A., Fontanini, G., Crinò, L. & Cappuzzo, F., Aug 15 2019, In : Clinical Cancer Research.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Exons
Mutation
Investigational Therapies

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials

Morabito, A., Piccirillo, M. C., Maione, P., Luciani, A., Cavanna, L., Bonanno, L., Filipazzi, V., Leo, S., Cinieri, S., Morgillo, F., Burgio, M. A., Ferrara, D., Rosetti, F., Bianco, R., Artioli, F., Cortinovis, D., Gebbia, V., Fregoni, V., Mencoboni, M., Sandomenico, C. & 10 others, Rossi, A., Montanino, A., Manzo, A., Rocco, G., Arenare, L., Daniele, G., Signoriello, S., Gallo, C., Perrone, F. & Gridelli, C., Jul 1 2019, In : Lung Cancer. 133, p. 62-68 7 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Cisplatin
Quality of Life
Drug Therapy
Mouth